Eylea May Help When Patients Do not Respond to Lucentis or Avastin for Macular Degeneration
A new study, published “online first” on May 23, 2013 in the American Journal of Ophthalmology, concludes that Eylea therapy appears to be beneficial in a specific group of patients with wet age-related macular degeneration (AMD) whose symptoms are not responsive to either Lucentis or Avastin injections. The American Journal of Ophthalmology is a peer-reviewed, … Continued